Literature DB >> 12672101

Assessment of specimen adequacy reproducibility: an Italian experience.

Gioia Montanari1, Massimo Confortini, Alberto Bellomi, Valeria Cocchi, Paolo Dalla Palma, Enrico D'Ambrosio, Maria Rosaria Giovagnoli, Roberto Navone, Guglielmo Ronco.   

Abstract

Interobserver disagreement on smear adequacy may influence the evaluation of the performance of samplers as well as Pap test sensitivity and follow-up. In 1998, the Italian Group for Cervical Cancer Screening (GISCi) promoted a study on the reproducibility of adequacy criteria using a modified version of the Bethesda system. A set of 200 smears was circulated among six Italian laboratories situated in different parts of the country. For each smear, participants were requested to provide a summary judgment on its adequacy and on the cause(s) of inadequacy, if any. Agreement was measured using kappa-type statistics. The agreement among laboratories was generally good. In comparisons, among five laboratories, kappa values ranged from 0.47 to 0.66. At the consensus meeting on 42 slides, on which at least 2 laboratories dissented from the majority, agreement was reached unanimously for 31 reviewed slides and among 5-6 centers for 11. In this article, some guidance is given in order to attribute to one of the two categories satisfactory/unsatisfactory those smears that have been traditionally considered as candidates for the category of "satisfactory but limited by em leader " (SBLB). New Italian guidelines on adequacy proposed the GISCi are presented and the recommendation is made to eliminate the SBLB category. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12672101     DOI: 10.1002/dc.10252

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  1 in total

1.  Do women >or=50 years of age need as much screening as women <50 years after they have had negative screening results?

Authors:  P Armaroli; F Gallo; A Bellomi; S Ciatto; D Consonni; D Davi; P Giorgi-Rossi; A Iossa; E Mancini; C Naldoni; E Polla; G Ronco; M Serafini; V Vergini; L Zanier; M Zappa; N Segnan
Journal:  Br J Cancer       Date:  2008-07-01       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.